These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19430004)

  • 21. Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
    Rössle M; Hirschmann A; Diebold J
    Eur J Cancer; 2011 Jun; 47(9):1305-11. PubMed ID: 21334201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P; Reichardt A
    Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
    Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
    Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
    Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA
    J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
    Gajiwala KS; Wu JC; Christensen J; Deshmukh GD; Diehl W; DiNitto JP; English JM; Greig MJ; He YA; Jacques SL; Lunney EA; McTigue M; Molina D; Quenzer T; Wells PA; Yu X; Zhang Y; Zou A; Emmett MR; Marshall AG; Zhang HM; Demetri GD
    Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1542-7. PubMed ID: 19164557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.
    Sjölund K; Andersson A; Nilsson E; Nilsson O; Ahlman H; Nilsson B
    World J Surg; 2010 Sep; 34(9):2090-7. PubMed ID: 20512492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X; Jiang WZ; Guan GX; Chen ZF; Chi P; Lu HS
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):221-5. PubMed ID: 23536339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sunitinib as a second-line therapy for imatinib-resistant gastrointestinal stromal tumors].
    Ishikawa T; Kanda T; Kosugi S; Yajima K; Hatakeyama K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):916-21. PubMed ID: 21677482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
    Blanke CD; Huse DM
    J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
    Kim EJ; Zalupski MM
    J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the treatment of gastrointestinal stromal tumours.
    Judson I; Demetri G
    Ann Oncol; 2007 Sep; 18 Suppl 10():x20-4. PubMed ID: 17761719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.
    Dizdar O; Yalcin S
    Hepatogastroenterology; 2011; 58(107-108):859-60. PubMed ID: 21830404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
    Shirao K; Nishida T; Doi T; Komatsu Y; Muro K; Li Y; Ueda E; Ohtsu A
    Invest New Drugs; 2010 Dec; 28(6):866-75. PubMed ID: 19730791
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
    Contreras-Hernández I; Mould-Quevedo JF; Silva A; Salinas-Escudero G; Villasís-Keever MA; Granados-García V; Dávila-Loaiza G; Petersen JA; Garduño-Espinosa J
    Br J Cancer; 2008 Jun; 98(11):1762-8. PubMed ID: 18506179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.
    Cauchi C; Somaiah N; Engstrom PF; Litwin S; Lopez M; Lee J; Davey M; Bove B; von Mehren M
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):977-82. PubMed ID: 22119758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.
    Wang WL; Conley A; Reynoso D; Nolden L; Lazar AJ; George S; Trent JC
    Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S15-24. PubMed ID: 21181476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal stromal tumors, version 2.2014.
    von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H
    J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.